Fructose-Induced Palmitate Synthesis in Overweight Subjects

Rockefeller University

Status and phase

Completed

Phase 1

Conditions

Diabetes

Elevated Triglycerides

Cardiovascular Disease

Treatments

Dietary Supplement: Fructose and Glucose

Dietary Supplement: Fructose

Study type

Interventional

Funder types

Other

Identifiers

NCT00535535

LHU-0616

Details and patient eligibility

About

Dietary fructose potently exacerbates the dyslipidemia associated with obesity, insulin resistance and accelerated atherosclerosis. In a randomized crossover outpatient study of 15 overweight adults, we will measure the increase over 4 hours in serum VLDL triglyceride palmitate made by the liver from each single oral dose of fructose (0.5 g/kg), fructose:glucose 1:1 (1 g/kg) or fructose:glucose 1:1 (2 g/kg). Our hypotheses are that the synthesis of palmitate from dietary fructose will be 1) greater when consumed with glucose and 2) show a dose-response. The lipogenic responses will be compared and correlated with markers of carbohydrate and lipid flux measured after fasting and post-fructose. The results will serve as a guide to the development of a new outpatient probe of the de novo lipogenic pathway in subjects who vary in their lipogenic response to oral fructose. These studies should ultimately yield valuable new information about the mechanisms linking dietary carbohydrate to elevated triglycerides, diabetes and cardiovascular disease.

Enrollment

15 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Males and females, 18-75 years of age
Body mass index (BMI) 25-35 and within 10% of maximum weight
Willing and able to stop fish oil, psyllium, other non-prescribed vitamins/supplements for 1 week prior to study until completion of study
Willing to not drink alcohol for 24 h before each day of blood sampling

Exclusion criteria

Diabetes or other endocrine disorder, hepatitis or other liver disorder, HIV, or autoimmune disease
Medication(s) known to affect lipids, including hormonal contraceptives
Recent acute illness
Gastrointestinal disease resulting in significant GI dysfunction or malabsorption
History of fasting TG >800 mg/dl
History of ethanol abuse (current intake >2 drinks/d) or illicit drugs
History of severe psychiatric illness
If female, pregnant or breastfeeding
Participation in an investigational drug study within one month of screening
Unusual diet or extreme level of physical activity
Have any other condition, which in the opinion of the investigator, should prohibit the participation in the study